Scripps, Sanofi Personalized Medicine Pact to Focus Initial PGx Research on Diabetes, Aging
A new personalized medicine partnership between Sanofi-aventis and Scripps Genomic Medicine will initially focus on using pharmacogenomics to individualize treatments for common diseases affecting metabolism and aging.
Read more on GenomeWeb News
Sanofi Bid to Block Lovenox Generic Taken `Under Advisement’ by U.S. Judge
A federal judge took under advisement a request by Sanofi-Aventis SA to bar U.S. regulators from allowing sales of a lower-cost rival to its Lovenox blood thinner.
Read more on Bloomberg
Related posts:
- Sanofi-Aventis, Genzyme discuss possible acquisition: Wall Street Journal
- Medco Research Institute and Leading French Researchers Launch Study Comparing Effient® and Double Dose of Plavix® in …
- Latest Generic Drugs News
- Personalized Approach to Smoking Cessation May Be Reality in Three to Five Years
- Latest Generic Drugs News
Tags: Aging, diabetes, Focus, initial, Medicine, Pact, Personalized, research, Sanofi, Scripps